GLP1 News and Research

RSS

Who gets obesity drugs covered by insurance? In North Carolina, it helps if you’re on Medicaid

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets don't work.

2 Dec 2024

Expert explores the expanding applications of GLP1 therapies

Researchers review recent advancements in glucagon-like peptide-1-based therapies.

28 Nov 2024

New oral peptide therapy offers hope for chronic abdominal pain

A research team at the University of Vienna, led by medicinal chemist Markus Muttenthaler, has developed a new class of oral peptide therapeutic leads for treating chronic abdominal pain.

22 Nov 2024

GLP-1 and SGLT2 inhibitors show promise in preventing recurrent stroke and heart attack

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death in adults who had an initial stroke, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2024.

11 Nov 2024

Ozempic effective for patients with chronic kidney damage

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic kidney disease and obesity.

28 Oct 2024

Study: GLP-1RA not associated with acute kidney injury risk during anti-cancer treatments

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear.

26 Oct 2024

New PET scan effectively detects benign insulinomas in the pancreas

A new PET scan reliably detects benign tumors in the pancreas, according to research led by Radboud university medical center.

21 Oct 2024

GLP1R medications show promise in reducing suicidal ideation among adolescents with obesity

Adolescents treated with GLP1R drugs for obesity exhibit fewer suicidal thoughts, indicating potential mental health benefits of these medications.

17 Oct 2024

Research reveals disparities in diabetes drug efficacy for Black populations

New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.

23 Sep 2024

Bariatric surgery outperforms GLP-1 medications in protecting kidney function

A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery was associated with a significant decrease in the progression of chronic kidney disease compared to those who received GLP-1 diabetes medications. The paper was published in Annals of Surgery.

20 Sep 2024

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

2 Sep 2024

ESC consensus statement highlights obesity's impact on cardiovascular disease

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2 September) summarizes current evidence on the epidemiology and etiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes.

30 Aug 2024

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

A study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with or without existing diabetes, while also achieving greater weight loss.

28 Aug 2024

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Whether antidiabetic medications could potentially be used as disease-modifying osteoarthritis drugs or DMOADs for the therapeutic management of osteoarthritis.

21 Aug 2024

$Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction$

Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction

A new small study led by Johns Hopkins Medicine researchers and published July 25th in the journal Nature Cardiovascular Research has revealed the impact of obesity on muscle structure in patients having a form of heart failure called heart failure with a preserved ejection fraction (HFpEF).

1 Aug 2024

Why millions are trying FDA-authorized alternatives to big pharma’s weight loss drugs

Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself "at my ideal body weight," with his cholesterol below 200 for the first time in 20 years. "I feel fantastic," he said.

23 Jul 2024

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) - prescription medications sold under popular drug names like Ozempic and Wegovy - in the United States.

22 Jul 2024

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Researchers evaluated the 12-month neurological and psychiatric outcomes of semaglutide use in patients with type 2 diabetes mellitus using a propensity-score matched cohort.

17 Jul 2024

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

15 Jul 2024

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Researchers identified distinct hindbrain GLP1R neurons driving satiety and aversion, offering new targets for effective, side-effect-free obesity treatments.

14 Jul 2024